Jefferies Financial Group Inc. Purchases 90,116 Shares of Sanofi $SNY

Jefferies Financial Group Inc. purchased a new position in shares of Sanofi (NASDAQ:SNY) during the 3rd quarter, Holdings Channel reports. The fund purchased 90,116 shares of the company’s stock, valued at approximately $3,715,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Allworth Financial LP grew its holdings in shares of Sanofi by 2.7% in the 2nd quarter. Allworth Financial LP now owns 9,233 shares of the company’s stock valued at $394,000 after acquiring an additional 243 shares in the last quarter. Euro Pacific Asset Management LLC increased its position in shares of Sanofi by 0.6% in the third quarter. Euro Pacific Asset Management LLC now owns 46,121 shares of the company’s stock valued at $1,902,000 after acquiring an additional 253 shares during the last quarter. Focused Alpha LLC increased its position in shares of Sanofi by 4.5% in the third quarter. Focused Alpha LLC now owns 6,553 shares of the company’s stock valued at $270,000 after acquiring an additional 281 shares during the last quarter. Intrua Financial LLC raised its holdings in Sanofi by 6.4% during the third quarter. Intrua Financial LLC now owns 5,100 shares of the company’s stock worth $210,000 after acquiring an additional 309 shares in the last quarter. Finally, Arkadios Wealth Advisors raised its holdings in Sanofi by 0.9% during the first quarter. Arkadios Wealth Advisors now owns 36,146 shares of the company’s stock worth $1,742,000 after acquiring an additional 315 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $48.46 on Friday. The business’s 50 day moving average price is $42.60 and its two-hundred day moving average price is $44.37. The company has a market cap of $117.49 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 1.33 and a beta of 0.31. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. Sanofi has a twelve month low of $39.07 and a twelve month high of $52.68.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.56 by $0.48. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The firm had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. During the same quarter in the prior year, the company earned $2.91 earnings per share. The business’s revenue for the quarter was up 16.2% compared to the same quarter last year. On average, analysts predict that Sanofi will post 5.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SNY. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, October 1st. DZ Bank reaffirmed a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. Royal Bank Of Canada began coverage on Sanofi in a research note on Tuesday, September 8th. They set a “sector perform” rating on the stock. Berenberg Bank reissued a “buy” rating on shares of Sanofi in a report on Monday, October 5th. Finally, Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $53.00.

Sanofi Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.